Posted by Michael Wonder on 12 Jan 2023
Pfizer's Paxlovid not included in China's national insurance
9 January 2023 - China will not include Pfizer’s COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price, saying it was too expensive.
Paxlovid, an oral medicine developed by New York-based drug maker Pfizer, has been widely sought after in China since the country began phasing out its “zero-COVID” restrictions and a surge of infections started sweeping through the country.
